Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6

Virology

Volumn 217, Issue 1, 1996, Pages 285-292

  Crook, Tim ^b   Ludwig, Robert L ^a   Marston, Nicola J ^a   Willkomm, Dagmar ^c   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; PROTEIN P53; UBIQUITIN;

ARTICLE; CONTROLLED STUDY; DNA BINDING; GENE MUTATION; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRUS;

EID: 0029863303     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0115     Document Type: Article

References (49)

1. Banks, L., Matlashewski, G., and Crawford, L. (1986). Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159, 529-534.
2. Cho, Y., Gorina, S., Jeffery, P. D., and Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355.
3. Chowdary, D. R., Dermody, J. J., Jha, K. K., and Ozer, H. L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14(3), 1997-2003.
4. Ciechanover, A. (1994). The ubiquitin-proteasome proteolytic pathway. Cell 79, 13-21.
5. Ciechanover, A., DiGiuseppe, J. A., Bercovich, B., Orian, A., Richter, J., Schwartz, A. L., and Brodeur, G. M. (1991). Degradation of nuclear oncogenes by the ubiquitin system in vitro. Proc. Natl. Acad. Sci. USA 88, 139-143.
6. Ciechanover, A., Shkedy, D., Oren, M., and Bercovich, B. (1994). Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J. Biol. Chem. 269, 9582-9589.
7. Crook, T., and Vousden, K. H. (1992). Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J. 11, 3935-3940.
8. Crook, T., Fisher, C., Masterson, P. J., and Vousden, K. H. (1994). Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9, 1225-1230.
9. Crook, T., Fisher, C., and Vousden, K. H. (1991a). Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol. 65, 505-511.
10. Crook, T., Tidy, J. A., and Vousden, K. H. (1991b). Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67, 547-556.
11. Di Leonardo, A., Linke, S. P., Clarkin, K., and Wahl, G. M. (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and longterm induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551.
12. El-Deiry, W., Tokino, T., Velculescu, V. E., Levy, D. B., Parson, V. E., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumour suppression. Cell 75, 817-825.
13. El-Deiry, W. S., Kern, S. E., Pietenpol, J A., Kinzler, K. W., and Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nat. Genet. 1, 45-49.
14. Foster, S. A., Demers, G. W., Etscheid, B. G., and Galloway, D. A. (1994). The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68, 5698-5705.
15. Fritsche, M., Haessler, C., and Brandner, G. (1993). Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307-318.
16. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
17. Halazonetis, T. D., Davis, L. J., and Kandil, A. N. (1993). Wild-type p53 adopts a "mutant"-like conformation when bound to DNA EMBO J. 12, 1021-1028.
18. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E., Smith-Sørensen, B., Montesano, R., and Harris, C. C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555.
19. Huibregtse, J. M., Scheffner, M., and Howley, P. M. (1991). A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10, 4129-4135.
20. Hupp, T. R., and Lane, D. P. (1994). Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp. Quant. Biol. 59, 195-206.
21. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. (1992). Regulation of the specific DNA binding function of p53. Cell 71, 875-886.
22. Jayaraman, L., and Prives, C. (1995). Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81, 1021-1029.
23. Juven, T., Barak, Y., Zauberman, A., George, D. L., and Oren, M. (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8, 3411-3416.
24. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311.
25. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. (1993). Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90, 3988-3992.
26. Lam, E. W. F., and Waston, R. J. (1993). An E2F-binding site mediates cell-cycle regulation repression of mouse B-myb transcription. EMBO J. 12, 2705-2713.
27. Lane, D. P. (1992). p53, guardian of the genome. Nature 358, 15-16.
28. Lechner, M. S., and Laimins, L. A. (1994). Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68, 4262-4273.
29. Maltzman, W., and Czyzyk, L. (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4, 1689-1694.
30. Marston, N. J., Crook, T., and Vousden, K. H. (1994). Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9, 2707-2716.
31. Matlashewski, G. J., Tuck, S., Pim, D., Lamb, P., Schneider, J., and Crawford, L. V. (1987). Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 7, 961-963.
32. Mietz, J. A., Linger, T., Huibregtse, J. M., and Howley, P. M. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 largeT-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11, 5013-5020.
33. Nelson, W. G., and Kastan, M. B. (1994). DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14, 1815-1823.
34. Oren, M. (1994). Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5, 221-227.
35. Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., and Vousden, K. H. (1996). Specific inactivation of the apoptotic function of p53 without loss of sequence specific transactivation and cell cycle arrest functions. EMBO J., in press.
36. Scheffner, M., Huibregtse, J. M., and Howley, P. M. (1994). Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA 91,8797-8801.
37. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
38. Scheffner, M., Münger, K., Huibregtse, J. M., and Howley, P. M. (1992a). Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J. 11, 2425-2431.
39. Scheffner, M., Takahashi, T., Huibregtse, J. M., Minna, J. D., and Howley, P. M. (1992b). Interaction of the human papillomavirus type 16 onco-protein with wild-type and mutant p53 proteins. J. Virol. 66, 5100-5105.
40. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
41. Smith, M. L., and Fornace, A. J. (1995). Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol. 7, 69-75.
42. Sun, X., Shimizu, H., and Yamamoto, K.-I. (1995). Identification of a novel p53 promoter element involved in gentoxic stress-inducible p53 gene expression. Mol. Cell. Biol. 15, 4489-4496.
43. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. (1992). An immunochemical analysis of the human nuclear phosphoprotein p53. J. Immunol. Methods 151, 237-244.
44. Wang, Y., and Prives, C. (1995). Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376, 88-91.
45. Werness, B. A., Levine, A. J., and Howley, P. M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248, 76-79.
46. Wilkinson, D., DeVries, R. R. P., Madrigal, J. A., Lock, C. B., Morgenstern, J. P., Trowsdale, J., and Altmann, D. (1988). Analysis of HLA-DR glyco-proteins by DNA mediated gene transfer. J. Exp. Med. 167, 1442-1458.
47. Wolkowicz, R., Peled, A., Elkind, N. B., and Rotter, V. (1995). Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 encoded by the regularly spliced form. Proc. Natl. Acad. Sci. USA 92, 6842-6846.
48. Zambetti, G. P., and Levine, A. J. (1993). A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7, 855-865.
49. zur Hausen, H. (1991). Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184, 9-13.